



ASX Release

4 September 2018

ZELDA THERAPEUTICS LIMITED
ACN 103 782 378

Level 26
140 St Georges Terrace,
Perth Western Australia 6000
Tel: +61 8 6558 0886
Fax: +61 8 6316 3337
E: enquiries@zeldatherapeutics.com
W: www.zeldatherapeutics.com

Contact

Dr Richard Hopkins
Managing Director
+61 405 656 868
rhopkins@zeldatherapeutics.com

Directors

Dr Richard Hopkins
Mr Harry Karelis
Dr Stewart Washer
Ms Mara Gordon
Mr Jason Peterson

Tickers:

Australia (ASX): ZLD
USA (OTC): ZLDAF

Ordinary Shares:

755,341,934

Options:

49,000,000

1,500,000 (\$0.04 – 6/2/2020)
*4,500,000 (\$0.04 – 6/2/2020)
1,000,000 (\$0.125 – 22/8/2021)
*3,000,000 (\$0.125 – 22/8/2021)

40,000,000 (\$0.03125 – 17/11/2021)
* subject to vesting conditions

Zelda Forms New Partnership to Access German Market

- **Zelda enters distribution and manufacturing strategic partnership with German medicinal cannabis group HAPA Medical**
- **Provides Zelda with ready access to the rapidly growing German market upon successful completion of clinical trials**
- **Provides HAPA with access to Zelda's clinically validated formulations**
- **Partnership enables value creation for both parties**
- **Zelda focused on rapid commercialisation of its products subject to success in clinical trials**

Zelda Therapeutics Limited (ASX:ZLD, OTCQB:ZLDAF) has entered a strategic partnership with German medicinal cannabis company HAPA Medical that provides HAPA with first rights to distribute and/or manufacture Zelda's clinically validated formulations into the rapidly growing German market.

HAPA (www.hapa-medical.com) is an early mover in the German medicinal cannabis market and is developing a vertically integrated business including cultivation, pharmaceutical-grade/GMP manufacturing, medical outreach, patient education and distribution to pharmacies and medical clinics across Germany.

Legislation on the broad use of medicinal cannabis in Germany passed in March 2017 that allows doctors to prescribe cannabis, including dried cannabis flower or cannabis extracts, to seriously ill patients even if other treatment options are available. Self-cultivation of cannabis and recreational use remain prohibited in Germany. Before the amendment, medical cannabis was only available to seriously ill patients with a special permit.

Under the German regulatory framework, the cost of cannabis-related medicines are potentially reimbursable for patients that register with their insurer. The subsidised nature of the medicinal cannabis industry in Germany has catalysed growth in the number of registered patients that has far exceeded initial forecasts.

This situation is different to the Australian and Canadian markets where there is limited or no health insurance subsidies for patients seeking to use medicinal cannabis as an alternative to existing subsidised medicines such as opiates.

With a population of 83 million people, Germany is estimated to have the potential to become the world's largest single medical cannabis market.

This partnership precedes Zelda completing various clinical trials and has been put in place to rapidly commercialise its clinically validated formulations.

Under the terms of the partnership, HAPA will be offered first rights to manufacture and/or distribute Zelda products that have successfully completed clinical trials. HAPA's in-house ability to manufacture specialised pharmaceuticals to GMP standards combined with its distribution network provides an attractive market entry pathway for Zelda.

No amounts will be received initially under this arrangement and all future receipts will come from the sale and distribution of Zelda's products into the German and European markets from this relationship.

Managing Director of Zelda, Dr Richard Hopkins stated, *"This partnership re-enforces the global breadth of Zelda's relationships and shows our focus on commercialising our clinically validated formulations. This is also important because Germany is expected to become the world's single largest market for medicinal cannabis."*

Managing Director of HAPA, Mr Ricardo Pendón stated, *"We are delighted to be entering this partnership with Zelda which is positioned as one of the world's leading science-driven medicinal cannabis companies. Growth in doctor and patient use is enabled by clinically validated data and having access to Zelda's pipeline of products is an important success factor for us."*

Tim Slate
Company Secretary

About Zelda Therapeutics (www.zeldatherapeutics.com)

Zelda Therapeutics Ltd ("Zelda") is an Australian-based bio-pharmaceutical company that is focused on developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions. The Company has a two-pronged strategy comprising:

- A **human clinical trial programme** focused on insomnia, autism and eczema with activities in Australia, Chile and the USA.
- A **pre-clinical research programme** examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

It has partnered with the world's leading cancer cannabis researchers at Complutense University Madrid in Spain to conduct certain pre-clinical work testing cannabis-based formulations known to have an effect in humans in order to generate data packs in a form expected by regulators and the pharmaceutical industry. A similar programme is in place with the Australian Telethon Kids Institute targeting paediatric brain cancer and Curtin University targeting pancreatic cancer and cognitive decline.